Does a Prostate Biopsy Damage the Prostate?

A prostate biopsy does cause temporary physical trauma to the gland, but the tissue overwhelmingly heals on its own within weeks to months. The procedure involves driving thin needles into the prostate to collect tissue samples, so some degree of local damage is unavoidable. What most people really want to know, though, is whether that damage lingers, whether it changes how the prostate works afterward, and whether it complicates future treatment if cancer is found. The answers depend on the type of biopsy, how many samples are taken, and your individual anatomy.

What Happens to the Prostate During a Biopsy

During a standard prostate biopsy, a spring-loaded needle fires into the gland and extracts a thin cylinder of tissue called a core. A typical session collects somewhere between 10 and 24 cores, sometimes more. Each puncture creates a small wound track through prostate tissue, disrupting glandular structures, tiny blood vessels, and surrounding connective tissue. The two main routes for the needle are through the rectal wall (transrectal) or through the skin between the scrotum and anus (transperineal). Both routes puncture the prostate itself in a similar way, but they differ in what other tissues the needle passes through on its way in, and that distinction has major consequences for infection risk and bleeding patterns.

The prostate’s response to this mechanical injury follows a predictable healing arc. Hemorrhage at the puncture sites is immediate and often visible on MRI for weeks afterward. One study examining pre-surgical MRI scans found that hemorrhage was still detectable in over half of patients roughly five weeks after biopsy, and that rate jumped to about 80% when imaging was done sooner than that.

Bleeding and Blood in Semen

The most common side effect people notice after a prostate biopsy is blood showing up where it normally should not. Blood in urine, blood in semen, and rectal bleeding (if the biopsy went through the rectum) are standard post-procedure experiences, not signs that something went wrong. In a large screening-program study of over 5,800 transrectal biopsies, about 23% of men had blood in their urine lasting longer than three days, and roughly half experienced blood in their semen.¹ A more recent real-world study of transperineal biopsies under local anesthesia reported hematuria in about 30% and blood in semen in roughly 19% of patients, with most cases being mild.²

Blood in semen tends to be the most persistent and anxiety-inducing of these effects. A prospective study tracking men who could ejaculate after biopsy found that 90% experienced it, with an average duration of about four weeks. It took an average of six ejaculations before the semen cleared completely.³ While alarming to see, blood in semen after a biopsy is a mechanical consequence of needle tracks through highly vascular tissue and is not a sign of lasting prostate damage.

Infection Risk and How the Biopsy Route Matters

Infection is the complication where the choice of biopsy route makes the biggest practical difference. A transrectal biopsy drives the needle through the rectal wall, which is home to billions of gut bacteria. Even with antibiotic prophylaxis, some bacteria can be pushed into the prostate or bloodstream. One tertiary-care center in Lebanon reported a urosepsis rate of about 9% following transrectal biopsies, which is higher than most centers but illustrates the range.⁴ Sepsis is a serious, sometimes life-threatening complication, and rising antibiotic resistance has made transrectal infections harder to prevent.

The transperineal approach avoids the rectum entirely, and the infection numbers reflect it. The PREVENT randomized trial found zero infections in the transperineal group compared with about 1.6% grade-2-or-higher infections in the transrectal group.⁵ A meta-analysis of ten randomized trials found that the transperineal route cut the odds of hospitalization for infectious complications by about 77% compared with transrectal biopsy.⁶ A separate systematic review specifically looked at transperineal biopsies and found the sepsis rate was only about 0.13%, and antibiotics did not significantly change that number.⁷

A head-to-head comparison at a high-volume center also showed that the transperineal route had a lower overall complication rate (about 55% vs. 82% for transrectal), lower rates of hematuria and rectal bleeding, and zero cases of prostatitis compared with three cases after transrectal procedures.⁸ This shift in evidence is why many urology guidelines now favor the transperineal approach as the default.

Temporary Urinary Problems

The prostate wraps around the urethra, so swelling after multiple needle passes can temporarily squeeze the urinary channel. Urinary retention, where you cannot empty your bladder after the procedure, happens in a meaningful minority of men. Two studies of transperineal template biopsies found retention rates of roughly 13% and 14%, respectively.⁹¹⁰ That usually means temporary catheterization for a couple of days.

Prostate size is the strongest predictor of retention. One of those studies found that men who developed retention had a median prostate volume of 75 cc compared with 40 cc in those who did not, and a volume cutoff of about 58 cc was a useful predictor.¹⁰ The number of cores also mattered: taking more than about 23 cores significantly raised the risk. In a study of over 1,100 transrectal biopsies, existing lower urinary tract symptoms and chronic constipation were additional risk factors for retention.¹¹ Nearly all men who develop retention after biopsy recover within days, and it rarely becomes a lasting issue.

Effects on Erectile Function

This is the question many men are most anxious about, and the honest answer is that temporary erectile changes are common but permanent dysfunction from a biopsy alone is rare. A study tracking men after transperineal template biopsies found that about 31% reported a measurable drop in erectile function in the first four weeks.¹² However, that dip was temporary for most. Among men under 60 who had no prior erectile problems and did not undergo treatment, 75% recovered normal function by three to nine months. In men over 60, recovery dropped to about 40%, and in men older than 68, only one in six fully recovered.¹²

The mechanisms behind post-biopsy erectile changes are a mix of physical and psychological factors. The needle passes can cause temporary inflammation and bruising around the neurovascular bundles that run alongside the prostate. Anxiety about the procedure itself, about the cancer diagnosis that may follow, and worry about sexual performance can all compound the physical effect.¹³ The number of cores taken and whether a periprostatic nerve block was used may also play a role, though the exact contributions remain debated. What is clear is that for younger men with good baseline function, the prostate’s nerve supply generally heals well after biopsy. Older men and those with pre-existing vascular or erectile issues have less margin for recovery.

How Biopsy Timing Affects Later Surgery

If cancer is found and surgery is recommended, the biopsy’s damage to the prostate becomes relevant in a different way. Surgeons performing a radical prostatectomy need to dissect along the prostate’s surface, and post-biopsy scarring, inflammation, and hemorrhage in the tissue can make that dissection more difficult. A large study examining over 7,300 radical prostatectomies found that men who waited 12 to 26 weeks between biopsy and surgery had the highest likelihood of nerve-sparing surgery, while those rushed to the operating room within four to six weeks had a higher rate of perioperative complications.¹⁴

Post-biopsy hemorrhage is also visible on MRI and can obscure the images used to plan nerve-sparing surgery. A study of pre-surgical MRI timing found that scans done too soon after biopsy were more likely to be discordant with surgical findings, and that waiting beyond about five weeks improved the accuracy of MRI for nerve-sparing decisions.¹⁵ The practical takeaway is that biopsy damage does not permanently compromise the prostate’s surgical landscape, but the tissue needs time to heal for the best surgical outcomes.

Can Fewer Needle Cores Reduce the Impact?

One of the most promising developments in reducing biopsy-related trauma is the shift from systematic (untargeted) biopsies to MRI-guided targeted biopsies. In a systematic biopsy, the urologist samples the prostate on a grid pattern, often taking 12 or more cores without knowing exactly where suspicious tissue is. MRI-targeted biopsy uses imaging to identify specific areas of concern and directs the needle only to those spots. A study comparing the two approaches in men getting their first biopsy found that MRI-targeted biopsies detected cancer equally well while requiring about 63% fewer cores.¹⁶

A large teaching hospital study explored taking the approach even further, performing only targeted cores without any systematic sampling in men with suspicious MRI findings. Omitting the systematic cores cut the number of cores by 75% per procedure, though it missed about 9% of clinically significant tumors.¹⁷ That tradeoff is still being debated, but the direction is clear: fewer needle passes mean less swelling, less bleeding, lower risk of retention, and a faster return to normal function. If you are being scheduled for a prostate biopsy, asking whether MRI-targeted biopsy is available is a reasonable conversation to have with your urologist.

Does a Biopsy Spread Cancer?

A concern that surfaces in online forums is whether a needle driven through a tumor could drag cancer cells along the needle track and seed them elsewhere. This fear is understandable but largely unsupported by evidence. A literature review identified 42 reported cases of needle-tract seeding across all published reports, with most occurring after transperineal biopsies (which pass through the perineal skin). Despite the dramatic increase in the number of biopsies performed worldwide and the number of cores taken per session over the years, the total number of reported seeding cases has not risen, and the overall incidence sits well below 1%.¹⁸ In clinical practice, this is considered a negligible risk that does not influence the decision to biopsy.

Pain and Tolerability

How much a biopsy hurts depends partly on the approach and partly on the anesthesia. Transperineal biopsies under local anesthesia have become increasingly common, and patient-reported data suggests they are well tolerated. In one prospective study, about 87% of men rated the biopsy-taking portion of the procedure as grade 3 or less on a pain scale (mild discomfort), and nearly 98% described the overall experience as tolerable. Only about 2% said they would prefer general anesthesia if they needed to do it again.² The local anesthetic injection itself was the more uncomfortable part for some men, with about 17% rating it as moderate pain and roughly 9% as more than moderate. Still, the fact that the overwhelming majority would repeat the procedure under local anesthesia is reassuring for anyone dreading the experience.

The number of cores taken and whether a periprostatic nerve block is used can influence pain. One study identified both the number of cores beyond 20 and the use of a nerve block itself as risk factors for complications, though that finding reflects a complex interaction where more complex procedures tend to involve more anesthesia and more tissue sampling simultaneously.¹⁹

Post-Biopsy Inflammation and the Prostate’s Tissue Response

Beyond the acute symptoms you can feel, the biopsy triggers microscopic changes in prostate tissue that pathologists see under the microscope. A study examining biopsy cores found chronic inflammation in about 77% of samples, and a specific pattern called proliferative inflammatory atrophy was the most common tissue response, strongly correlated with the intensity of inflammation.²⁰ It is worth noting that this study was examining inflammation as a feature associated with cancer detection, not as a consequence of prior biopsy injury. The prostate is an organ prone to chronic inflammation for many reasons, and disentangling biopsy-related inflammation from pre-existing background inflammation is something pathologists navigate regularly. The key point for patients is that any biopsy-induced inflammation is self-limiting and does not set the gland on a path toward new disease.

When Repeat Biopsies Compound the Issue

Many men do not have just one biopsy. If an initial biopsy is negative but clinical suspicion persists, or if a man is on active surveillance for low-grade cancer, repeat biopsies are common. Each round of sampling creates a new set of needle tracks through previously biopsied tissue. Cumulative scarring and inflammation can make the prostate firmer and less compliant over time, which some men describe as increased urinary symptoms between biopsy rounds. The shift toward MRI-targeted biopsies is particularly valuable in the repeat-biopsy setting, because it allows clinicians to sample only suspicious areas rather than blanketing the entire gland again. For men on active surveillance, who may face biopsies every one to three years for a decade or more, the reduction in core count per session meaningfully lowers the cumulative tissue disruption.

Repeat biopsies also compound the imaging challenge for surgeons. Each biopsy leaves artifact, small areas of hemorrhage and scar, that can mimic or obscure tumor on MRI. Allowing adequate time between a biopsy and subsequent imaging is even more important in men who have had multiple prior biopsies, because the cumulative artifact can make tumor borders harder to define.

1
PubMed. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program
2
PubMed Central. Patient-reported outcome measures for pain and tolerability of transperineal prostate biopsy under local anaesthesia using the PrecisionPoint™ transperineal access system
3
PubMed Central. Hemosepermia after transrectal ultrasound-guided prostatic biopsy: A prospective study
4
PubMed Central. Incidence of sepsis following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon
5
JAMA Oncology. Transperineal vs Transrectal Prostate Biopsy—The PREVENT Randomized Clinical Trial
6
PubMed. Infectious Complications After Transrectal Versus Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis
7
Prostate Cancer and Prostatic Diseases. Infectious complications following transperineal prostate biopsy with or without periprocedural antibiotic prophylaxis—a systematic review including meta-analysis of all comparative studies
8
PubMed Central. Complication rates of transrectal and transperineal prostate fusion biopsies – is there a learning curve even in high volume interventional center?
9
PubMed. Factors influencing urinary retention after transperineal template biopsy of the prostate: outcomes from a regional cancer centre
10
PubMed Central. Factors influencing urinary retention following freehand transperineal prostate biopsy: Insights from a tertiary care center study
11
PubMed Central. Effect of constipation on acute urinary retention following transrectal prostate biopsy
12
PubMed Central. Predictors of erectile dysfunction after transperineal template prostate biopsy
13
International Archives of Urology and Complications. The Effect of Prostate Biopsy on Erectile Functions
14
PubMed Central. Impact of time from biopsy to surgery on complications, functional and oncologic outcomes following radical prostatectomy
15
PubMed Central. The optimal timing of post-prostate biopsy magnetic resonance imaging to guide nerve-sparing surgery
16
PubMed Central. MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men
17
PubMed Central. Outcomes of a Diagnostic Pathway for Prostate Cancer Based on Biparametric MRI and MRI-Targeted Biopsy Only in a Large Teaching Hospital
18
PubMed. Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature
19
Insight Urology. Factors predicting complications after transrectal ultrasound guided prostate biopsy
20
PubMed Central. Inflammation and focal atrophy in prostate needle biopsy cores and association to prostatic adenocarcinoma